Trends in 1-year persistence and adherence among initiators of high-potency, weight loss–indicated glucagon-like peptide 1 receptor agonists

This real-world analysis of high-potency, weight loss-indicated GLP-1RA products among individuals without diabetes found that 1-year treatment persistence has nearly doubled from 33.2% in 2021 to 60.9% in 1H 2024. GLP-1RA product shortage resolution may have improved persistence rates. Other potential influencing factors include improved GLP-1RA dose escalation and side effect management, as well as weight loss lifestyle management programs. Additional research is needed to understand treatment discontinuation reasons and long-term GLP-1RA cost-effectiveness.